Genome-wide screening for the G-protein-coupled receptor (GPCR) pathway-related therapeutic gene RGS19 (regulator of G protein signaling 19) in bladder cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Sridhar SS. Evolving treatment of advanced urothelial cancer. J Oncol Pract. 2017;13(5):309–315.
   PubMed Web of Science ®Google Scholar
• Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41.
   PubMed Web of Science ®Google Scholar
• Becker REN, Meyer AR, Brant A, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. 2021;79(3):364–371.
   PubMed Web of Science ®Google Scholar
• Chang SS, Bochner BH, Chou R, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017;198(3):552–559.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82–104.
   PubMed Web of Science ®Google Scholar
• Westergren DO, Gårdmark T, Lindhagen L, et al. A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014. J Urol. 2019;202(5):905–912.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077.
   PubMed Web of Science ®Google Scholar
• Lenis AT, Lec PM, Chamie K, et al. Bladder Cancer: a Review. JAMA. 2020;324(19):1980–1991.
   PubMed Web of Science ®Google Scholar
• Montazeri K, Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2020;13(1):1–6.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021;39(22):2474–2485.
   PubMed Web of Science ®Google Scholar
• Ross EM, Gilman AG. Biochemical properties of hormone-sensitive adenylate cyclase. Annu Rev Biochem. 1980;49(1):533–564.
   PubMedGoogle Scholar
• Hauser AS, Attwood MM, Rask-andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications Alexander. Nat Rev Drug Discov. 2019;16(12):829–842.
   Web of Science ®Google Scholar
• Sriram K, Insel PA, Protein-Coupled G. Receptors as Targets for Approved Drugs: how Many Targets and How Many Drugs? Mol Pharmacol. 2018;93(4):251–258.
   PubMed Web of Science ®Google Scholar
• Hutter C, Zenklusen JC. The Cancer Genome Atlas: creating Lasting Value beyond Its Data. Cell. 2018;173(2):283–285.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Furumichi M, Tanabe M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–D361.
   PubMed Web of Science ®Google Scholar
• Gu Z, You Z, Yang Y, et al. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways. Bioengineered. 2021;12(1):4719–4735.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.
   PubMed Web of Science ®Google Scholar
• Vitale I, Galluzzi L, Castedo M, et al. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;12(6):385–392.
   PubMed Web of Science ®Google Scholar
• De Vries L, Mousli M, Wurmser A, et al. GAIP, a protein that specifically interacts with the trimeric G protein Gαi3, is a member of a protein family with a highly conserved core domain. Proc Natl Acad Sci U S A. 1995;92(25):11916–11920.
   PubMed Web of Science ®Google Scholar
• Hurst JH, Hooks SB. Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol. 2009;78(10):1289–1297.
   PubMed Web of Science ®Google Scholar
• De Vries L. RGS proteins: more than just GAPs for heterotrimeric G proteins. Trends Cell Biol. 1999;9(4):138–144.
   PubMed Web of Science ®Google Scholar
• Soundararajan M, Willard FS, Kimple AJ, et al. Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc Natl Acad Sci U S A. 2008;105(17):6457–6462.
   PubMed Web of Science ®Google Scholar
• Tso PH, Wang Y, Wong SY, et al. RGS19 enhances cell proliferation through its C-terminal PDZ motif. Cell Signal. 2010;22(11):1700–1707.
   PubMed Web of Science ®Google Scholar
• Fischer T, De Vries L, Meerloo T, et al. Promotion of Gαi3 subunit down-regulation by GIPN, a putative E3 ubiquitin ligase that interacts with RGS-GAIP. Proc Natl Acad Sci U S A. 2003;100(14):8270–8275.
   PubMed Web of Science ®Google Scholar
• Hurst JH, Mendpara N, Hooks SB. Regulator of G-protein signalling expression and function in ovarian cancer cell lines. Cell Mol Biol Lett. 2009;14(1):153–174.
   PubMed Web of Science ®Google Scholar
• Kirikoshi H, Katoh M. Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors. Int J Mol Med. 2002;9(5):509–513.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang Y, Gao J, et al. The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data. Bioengineered. 2020;11(1):572–581.
   PubMed Web of Science ®Google Scholar
• Wan S, Liu X, Hua W, et al. The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer. Bioengineered. 2021;12(1):1495–1504.
   PubMed Web of Science ®Google Scholar
• Lee EK, Ye Y, Kamat AM, et al. Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer. 2013;119(9):1643–1651.
   PubMed Web of Science ®Google Scholar
• Deng M, Wei W, Duan J, et al. ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21. Cancer Sci. 2021;112(5):1758–1771.
   PubMed Web of Science ®Google Scholar
• Berman DM, Wang Y, Liu Z, et al. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res. 2004;64(18):6820–6826.
   PubMed Web of Science ®Google Scholar
• Li G, Wang M, Ren L, et al. Regulator of G protein signaling 20 promotes proliferation and migration in bladder cancer via NF-κB signaling. Biomed Pharmacother. 2019;117:109112.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tong Y, Tso PH, et al. Regulator of G protein signaling 19 suppresses Ras-induced neoplastic transformation and tumorigenesis. Cancer Lett. 2013;339(1):33–41.
   PubMed Web of Science ®Google Scholar
• Tso PH, Yung LY, Wang Y, et al. RGS19 stimulates cell proliferation by deregulating cell cycle control and enhancing Akt signaling. Cancer Lett. 2011;309(2):199–208.
   PubMed Web of Science ®Google Scholar
• Sadaie M, Dillon C, Narita M, et al. Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition. Mol Biol Cell. 2015;26(17):2971–2985.
   PubMed Web of Science ®Google Scholar
• Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene. 2015;34(5):537–545.
   PubMed Web of Science ®Google Scholar
• Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 2016;94(12):1313–1326.
   PubMed Web of Science ®Google Scholar
• Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2(1):21–32.
   PubMed Web of Science ®Google Scholar
• Hardwicke MA, Oleykowski CA, Plant R, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009;8(7):1808–1817.
   PubMed Web of Science ®Google Scholar
• Adams ND, Adams JL, Burgess JL, et al. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010;53(10):3973–4001.
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC, Glover DM. The Dawn of Aurora Kinase Research: from Fly Genetics to the Clinic. Front Cell Dev Biol. 2015;3:73.
   PubMed Web of Science ®Google Scholar
• Willems E, Dedobbeleer M, Digregorio M, et al. The functional diversity of Aurora kinases: a comprehensive review. Cell Div. 2018;13(1):7.
   PubMedGoogle Scholar
• Vader G, Kauw JJ, Medema RH, et al. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep. 2006;7(1):85–92.
   PubMed Web of Science ®Google Scholar
• Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol. 2006;173(6):833–837.
   PubMed Web of Science ®Google Scholar
• Kelly AE, Sampath SC, Maniar TA, et al. Chromosomal enrichment and activation of the aurora B pathway are coupled to spatially regulate spindle assembly. Dev Cell. 2007;12(1):31–43.
   PubMed Web of Science ®Google Scholar